Vladimir K. Tatochenko

Vladimir K. Tatochenko

Auto-generated profile, based on publicly available information

Vladimir K. Tatochenko

National Medical Research Center of Children’s Health

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2014 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
VTV. K. Tatochenko
V. K. Tatochenko
КОКЛЮШ — НЕДОУПРАВЛЯЕМАЯ ИНФЕКЦИЯ

20 August 2020 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
YAYurii S. Alexandrovich
Yurii S. Alexandrovich
EAEkaterina I. Alekseeva
Ekaterina I. Alekseeva
MBMaya D. Bakradze
Maya D. Bakradze
ABAlexander A. Baranov
Alexander A. Baranov
TBTatiana T. Batysheva
Tatiana T. Batysheva
АЯА. В. Яковлев
А. В. Яковлев
The Ministry of Health of the Russian Federation jointly with professional association and experts in the field of pediatrics, infectious diseases and resuscitation has revised guidelines “Clinical Features and Management of the Disease Caused by New Coronaviral Infection (COVID-19) in Children” in order to provide the child population with effective medical care during the pandemic of the new coronaviral infection. The practical experience of specialists from various countries was considered during the development of this document. Special attention should be given to the evidence base of the presented data, as well as to the efficiency and safety issues of medications used in treatment of coronaviral infection and its complications. The authors highlight the problems of prevention, diagnostics and management of pathological conditions caused by COVID-19 in the article according to the presented guidelines. Patient’s management is presented depending on the age and severity of the disease itself. The therapy is considered with regard to etiological, pathogenetic and symptom focus.

31 March 2021 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Verified
Journal Article
Open access
PDF file
VTV. K. Tatochenko
V. K. Tatochenko
Pneumonia in children remains one of the most serious diseases. Despite intensive study, the diagnosis and treatment still present a variety of problems. The article is aimed to identify these problems and show the ways of their solution.One of the criteria for the diagnosis of pneumonia is pulmonary infiltrate on the X-ray image. Community-acquired pneumonia is often caused by Pneumococci and mycoplasma; respiratory viruses, influenza usually serve as contributing factors for bacterial infection. The high level of hyperand underdiagnosis of community-acquired pneumonia is associated with its similarity with ARVI; the registration of general violations (signs of the severity of the disease) improves the quality of diagnosis. The clinical and radiological picture helps to distinguish pneumococcal pneumonia from pneumonia caused by mycoplasma. To improve the diagnosis of community-acquired pneumonia, it is necessary to study inflammation markers during the first examination of the patient, which is impossible in the conditions of home care. Due to the growth of resistance of pneumococci to macrolides a community-acquired pneumonia of pneumococcal (and unclear) etiology requires the use of amoxicillin in high doses and macrolides (in case of atypical pneumonia). Gentle therapy of destructive pneumonia, steroids for metapneumonic pleurisy allow avoiding invasive interventions and help to repair lung tissue.

6 July 2018 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
ABAlexander A. Baranov
Alexander A. Baranov
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
NBNikolay I. Brico
Nikolay I. Brico
YLYurii V. Lobzin
Yurii V. Lobzin
RКRoman S. Коzlov
Roman S. Коzlov
СХС. Р. Харит
С. Р. Харит
Pneumococcal infection remains one of the leading reasons for infant mortality from vaccine-preventable infections. Today vaccination is the most effective way to prevent diseases caused by antibiotic-resistant pneumococci. In the article, authors present current approaches to vaccinal prevention of pneumococcal diseases. The plan of action for carrying out active immunoprophylaxis of pneumococcal infection is explained in detail for both healthy children and patients from risk groups for severe pneumococcal diseases development. The published work is based on key points of the guidelines of the Ministry of Health of the Russian Federation on vaccinal prevention of pneumococcal infection (developed and approved by the professional association of pediatricians «The Union of Pediatricians of Russia»).

8 March 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
AMAlen Marijam
Alen Marijam
ESEkaterina Safonova
Ekaterina Safonova
MSMikhail Scherbakov
Mikhail Scherbakov
ESEvgeniy Shpeer
Evgeniy Shpeer
DODesirée Van Oorschot
Desirée Van Oorschot
NBNikolay Briko
Nikolay Briko
This economic evaluation assesses the cost-effectiveness and budget impact of introducing a two-dose varicella vaccine in the Russian national immunization program. A static Markov model followed a simulated 2019 Russian cohort over its lifetime and compared outcomes and costs of three varicella vaccination strategies: strategy I (doses given at 12 and 15 months of age), strategy II (doses given at 1 year and 6 years of age), and a no vaccination scenario. Inputs on age-dependent clinical pathways, associated costs, and related health outcomes were collected from national sources and published literature. Results are presented as incremental cost-effectiveness ratio (ICER) from the healthcare payer and societal perspective over the lifetime of the birth cohort and the budget impact over a 10 years’ time horizon. Vaccination strategies I and II resulted in an ICER of approximately 1.7 million rubles per quality-adjusted life years gained from the healthcare payer perspective and were cost-saving from the societal perspective. From the healthcare payer perspective, the costs per varicella case averted were 5,989 and 7,140 rubles per case for strategies I and II, respectively. However, from the societal perspective, vaccination is a dominant strategy and the budget impact analysis shows significant healthcare savings over 10 years, with strategy I realizing savings of ~2 billion rubles more than strategy II. From a public health impact perspective, varicella vaccination of children at 12 and 15 months of age through the Russian NIP is expected to be cost-effective with an affordable budget impact compared to no vaccination. A graphical version of the plain language summary can be found here: 10.6084/m9.figshare.19291463 Focus on the patient What is the context? What is new? What is the impact? Graphical Abstract

3 November 2015 in Pediatric pharmacology
Verified
Journal Article
Open access
AБArray А. Баранов
Array А. Баранов
LNL. S. Namazova-Baranova
L. S. Namazova-Baranova
VTV. K. Tatochenko
V. K. Tatochenko
IDI. V. Davydova
I. V. Davydova
MBM. D. Bakradze
M. D. Bakradze
APA. S. Polyakova
A. S. Polyakova
Статья посвящена проблеме острого бронхиолита у детей. Актуальность данной проблемы не вызывает сомнений: по самым скромным подсчетам, ежегодно во всем мире регистрируется более 150 млн случаев бронхиолита, 7–13% из которых требуют стационарного лечения, а 1–3% — госпитализации в отделение интенсивной терапии. Наиболее часто этиологическим фактором выступают вирусы — респираторно-синцитиальный (подавляющее большинство случаев — 90%), значимым агентом является риновирус, а также вирусы гриппа А и В, парагриппа, аденовирус, коронавирус, метапневмовирус и бокавирус человека. Развитие бронхиолита у детей первых двух лет жизни может обусловить целый ряд факторов. Особенно тяжело бронхиолит протекает у недоношенных, детей с бронхолегочной дисплазией и на искусственном вскармливании, а также у пациентов с врожденными пороками развития и иммунодефицитами. Специалистами профессиональной ассоциации детских врачей — Союза педиатров России — в соответствии с принципами доказательной медицины сформулированы и кратко изложены основополагающие критерии диагностики, алгоритмы терапии и дальнейшего ведения пациентов с данной патологией.